TSW
MRNA icon

Thompson Siegel & Walmsley’s Moderna MRNA Stock Holding History

Thompson Siegel & Walmsley’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-143
Closed -$22K – 549
2023
Q1 		$22K Hold
143
– – ﹤0.01% 464
2022
Q4 		$26K Hold
143
– – ﹤0.01% 446
2022
Q3 		$17K Hold
143
– – ﹤0.01% 464
2022
Q2 		$20K Hold
143
– – ﹤0.01% 455
2022
Q1 		$25K Sell
143
-107
-43% -$18K ﹤0.01% 495
2021
Q4 		$63K Hold
250
– – ﹤0.01% 466
2021
Q3 		$96K Buy
+250
New +$92.2K ﹤0.01% 421

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Thompson Siegel & Walmsley's MRNA Position: Q2 2023 in Review

Thompson Siegel & Walmsley sold out of Moderna (MRNA) in Q2 2023, closing a stake of 143 shares — an estimated $22K sold.

Thompson Siegel & Walmsley first reported a position in MRNA in Q3 2021 and held it in 7 quarters. The position peaked at $96K in Q3 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Thompson Siegel & Walmsley reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 143 Moderna shares in Q2 2023, an estimated $22K.
  • Thompson Siegel & Walmsley first reported a position in Moderna in Q3 2021 and held it in 7 quarters.
  • Thompson Siegel & Walmsley's Moderna position peaked at $96K in Q3 2021.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2023, filed 10 Aug 2023.